Bal Pharma Ltd (BALPHARMA) is currently trading at 72.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bal Pharma Ltd (BPL) is part of the Mcro Laboratories Group, specializing in the manufacture and marketing of pharmaceutical formulations like paracetamol, gliclazide, etc. The company has progressively expanded its product range and entered cardiac specialities, utilizing divisions like 'SERVETUS' for dedicated marketing. BPL has recently launched new drug formulations like Sitagliptin and its combination with Metformin, indicating product innovation. Historically, BPL has engaged in strategic acquisitions, such as Golden Drugs Pvt Ltd, enhancing its manufacturing capabilities and portfolio diversification. The company's ongoing investment in an integrated API unit reflects its commitment to expanding production capacity and operational scope.

Over the past 52 weeks, Bal Pharma Ltd has traded between a low of ₹67.15 and a high of ₹128.86. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bal Pharma Ltd has a market capitalization of approximately 114.41. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bal Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.75 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Bal Pharma Ltd (BALPHARMA) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 114.41 Cr, Bal Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bal Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bal Pharma Ltd is 16.75. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Bal Pharma Ltd pays dividends with a current dividend yield of 1.67%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Bal Pharma Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.